Dec 24 (Reuters) - The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.

The drug, Namzaric, is designed to treat moderate-to-severe dementia in Alzheimer's patients who are stabilized with other drugs.

Namzaric combines two ingredients in drugs often prescribed together for Alzheimer's in a single capsule.

(Reporting by Natalie Grover in Bengaluru; Editing by Joyjeet Das)